The CD44 molecule is also physically linked with the product of the HER-2/neu oncogene —tyrosine kinase and EGF receptor, the expression of which predict poor prognosis in breast and ovarian cancers, and in 9 % of ECs (but in 27 % of metastatic ECs) [7, 28, 40]. This evidence concerns the gene CD44 and ovarian cancer.